Daily Cosmetic Research Analysis
Analyzed 23 papers and selected 3 impactful papers.
Summary
A prospective cohort study found that pregnancy outcomes after fertility-preserving vNOTES are comparable to controls with no need to delay conception. A mechanistic preclinical study identified an adipose-derived stem cell peptide (ADSCP5) that attenuates hypertrophic scarring via coordinated suppression of PI3K/AKT/mTOR and NF-κB signaling. Another mechanistic study showed TRIM9 stabilizes β-catenin in dermal papilla cells, offering a target for androgenetic alopecia.
Research Themes
- Fertility-preserving minimally invasive gynecologic surgery and cosmetic outcomes
- Anti-fibrotic therapeutics for hypertrophic scarring
- Molecular targets for hair regeneration in androgenetic alopecia
Selected Articles
1. Obstetrical outcomes after transvaginal natural orifice transluminal endoscopic surgery for benign gynecological conditions: a prospective cohort study.
In a prospective cohort of 326 post‑vNOTES pregnancies matched to 326 controls, delivery mode, gestational age, neonatal weight, and maternal complications were comparable. Twin pregnancy, not the surgery-to-conception interval, independently increased risks of preterm birth and neonatal asphyxia. Early conception after vNOTES appeared safe.
Impact: This is a well-designed prospective cohort with matched controls directly informing counseling on timing of conception after vNOTES, a technique valued for minimal scarring.
Clinical Implications: Patients desiring pregnancy after vNOTES do not appear to require prolonged delay; obstetrical outcomes were similar to controls. Counseling should emphasize that twin pregnancy, rather than surgical timing, drives preterm/asphyxia risk.
Key Findings
- Obstetrical outcomes (delivery mode, gestational age, neonatal birth weight, maternal complications) were comparable between vNOTES and controls.
- The interval between vNOTES and conception was not associated with adverse outcomes.
- Twin pregnancy independently increased risks of preterm birth (HR 11.736) and neonatal asphyxia (HR 29.302); lower gestational age associated with asphyxia.
Methodological Strengths
- Prospective cohort with matched controls and multivariable regression
- Prospective trial registration (ChiCTR2200059282)
Limitations
- Non-randomized design with baseline differences (parity, prior cesarean) between groups
- Indication distribution varied across surgery‑to‑conception interval strata; single‑country context may limit generalizability
Future Directions: Multicenter prospective registries and randomized comparative effectiveness studies could refine risk estimates and assess long-term pelvic floor, sexual function, and cosmetic outcomes post‑vNOTES.
BACKGROUND: Transvaginal natural orifice transluminal endoscopic surgery (vNOTES) is increasingly used for benign gynecologic conditions; however, evidence regarding subsequent obstetrical outcomes and the optimal interval between surgery and conception remains limited. This study aimed to evaluate pregnancy outcomes after fertility-preserving vNOTES and to assess whether the postoperative interval influences the risk of adverse outcomes. METHODS: This prospective cohort study included 326 women who conceived after fertility-
2. Adipose-derived stem cell peptide 5 alleviates hypertrophic scarring through targeting pyruvate carboxylase or p50 to coordinate PI3K/AKT/mTOR-autophagy and NF-κB/IL-6 signaling.
ADSCP5 reduced collagen and α‑SMA expression in hypertrophic scar fibroblasts without impairing viability, suppressed PI3K/AKT/mTOR and NF‑κB/IL‑6 signaling via direct binding to pyruvate carboxylase or p50, and induced ROS/autophagy. In rabbit and porcine scar models, ADSCP5 decreased collagen deposition and angiogenesis markers while increasing macrophage markers.
Impact: The study uncovers a mechanistic, target-engaged anti-fibrotic peptide with efficacy in two animal models, offering a translational path for hypertrophic scar prevention and treatment.
Clinical Implications: While preclinical, ADSCP5’s dual-pathway modulation suggests a candidate for intralesional or postoperative prophylaxis to reduce hypertrophic scarring. Dose, delivery vehicle, and safety profiling are needed before human trials.
Key Findings
- ADSCP5 downregulated COL1A1, COL1A2, COL3A1, and ACTA2 in hypertrophic scar fibroblasts without affecting proliferation, apoptosis, or migration.
- ADSCP5 suppressed p‑PI3K, p‑AKT, p‑mTOR, and p‑p65 and reduced IL‑6 transcription; it bound directly to pyruvate carboxylase or NF‑κB p50 with rescue assays confirming mechanism.
- ADSCP5 induced ROS and autophagy, modulated macrophage‑fibroblast crosstalk, and showed anti‑angiogenic effects in HUVECs.
- In rabbit and porcine scar models, ADSCP5 reduced collagen deposition and scar hyperplasia, increased CD68+ macrophages, decreased VEGFA/CD34, and reduced p62.
Methodological Strengths
- Mechanistic target engagement demonstrated (binding to PC/p50) with rescue assays
- Concordant efficacy across in vitro and two in vivo species (rabbit, porcine) with multimodal readouts
Limitations
- Preclinical models; no human pharmacokinetic, safety, or efficacy data
- Peptide delivery, stability, and dosing strategies require optimization for clinical translation
Future Directions: Define pharmacokinetics, biodistribution, and dosing; test intralesional formulations; and progress to phase I studies in high‑risk scar populations (e.g., sternotomy, burns).
BACKGROUND: Hypertrophic scars are a major clinical challenge with limited treatments. Adipose-derived stem cells (ADSCs) play an important role in inhibiting pathological scar formation. However, the underlying mechanisms remain unclear. In this study, we aimed to investigate the function, mechanism, and therapeutic potential of adipose-derived stem cell peptide 5 (ADSCP5), a novel peptide from adipose-derived stem cell-conditioned medium. METHODS: We used RESULTS: In hypertrophic scar fibroblasts, ADSCP5 significantly
3. TRIM9 regulates the proliferation and apoptosis of dermal papilla cells by activating the Wnt/β-catenin signaling pathway to improve androgenetic alopecia.
TRIM9 expression was reduced in AGA models. TRIM9 overexpression promoted hair growth in AGA mice, increased human DPC proliferation, and inhibited apoptosis. Mechanistically, TRIM9 competitively bound β‑TrCP, reduced β‑TrCP–mediated ubiquitination of β‑catenin, and activated Wnt/β‑catenin signaling; Wnt inhibition with XAV939 attenuated these effects.
Impact: This study identifies a druggable regulatory node—TRIM9/β‑TrCP/β‑catenin—in dermal papilla cells, linking E3 ligase biology to hair follicle signaling and offering a mechanistically grounded strategy for AGA.
Clinical Implications: Though preclinical, targeting TRIM9–β‑TrCP interaction or stabilizing β‑catenin in DPCs could guide development of topical or follicle‑directed therapies for AGA distinct from current DHT‑centric approaches.
Key Findings
- TRIM9 expression is downregulated in AGA; TRIM9 overexpression enhances hair growth in DHT‑induced AGA mice.
- TRIM9 promotes proliferation and inhibits apoptosis of human dermal papilla cells in vitro.
- TRIM9 competitively binds β‑TrCP, reduces β‑TrCP–mediated ubiquitination of β‑catenin, and activates Wnt/β‑catenin signaling; XAV939 partially reverses these effects.
Methodological Strengths
- Integrated in vivo (mouse AGA) and in vitro human DPC experiments
- Mechanistic validation via co‑immunoprecipitation, ubiquitination assays, and pharmacologic inhibition
Limitations
- Relies on overexpression models; endogenous modulation and off‑target effects need evaluation
- Translation to human clinical efficacy and safety remains untested
Future Directions: Develop small molecules or peptides that modulate TRIM9–β‑TrCP interaction; test follicle‑targeted delivery and durability of effect in large animal models before early human trials.
BACKGROUND AND PURPOSE: Dermal papilla cells (DPCs) are signaling hubs for hair follicle growth and play a critical role in hair growth in patients with androgenetic alopecia (AGA). TRIM9, a tripartite motif (TRIM)-family E3 ubiquitin ligase, regulates cell differentiation, proliferation, and apoptosis. This study aimed to investigate the effects of TRIM9 on the proliferation and apoptosis of DPCs. METHODS: AGA mouse and cellular models were induced by dihydrotestosterone (DHT) treatment to conduct experimental inves